Viracta Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Viracta Therapeutics announces it will terminate employees and wind down operations, exploring strategic alternatives for its development programs.
Viracta Therapeutics receives delisting notice from Nasdaq due to non-compliance with listing rules and expects its shares to trade on the OTC Pink Open Market.
Viracta Therapeutics enters into a forbearance agreement with its lenders, Oxford Finance LLC and Silicon Valley Bank, to avoid immediate exercise of remedies following previously disclosed events of default.
Viracta Therapeutics received a notice from Nasdaq regarding non-compliance with audit committee requirements following a director's resignation.
Viracta Therapeutics has defaulted on its loan agreement, is closing its Phase 2 clinical trial, and is exploring strategic alternatives including a potential sale or merger.
Viracta Therapeutics has received a delisting notice from Nasdaq after failing to meet the minimum bid price and stockholders' equity requirements, and intends to appeal the decision.
Viracta Therapeutics has received a notice from Nasdaq stating that it no longer meets the minimum stockholder equity requirement for continued listing.
Viracta Therapeutics announced its third quarter 2024 financial results, a reprioritization of resources towards its lymphoma program, and provided updates on its clinical trials.
Viracta Therapeutics is reducing its workforce by 42% and its board size to focus on its Nana-val cancer treatment program.
Viracta Therapeutics reported positive Phase 2 trial results for Nana-val in relapsed or refractory EBV-positive peripheral T-cell lymphoma, leading to a strategic shift in clinical development and a workforce reduction.
Viracta Therapeutics has committed to a workforce reduction impacting approximately 23% of its employees, with expected costs of around $0.7 million for severance and benefits.
Viracta Therapeutics held its 2024 annual meeting, electing four Class III directors, approving executive compensation, and ratifying its independent auditor.
Viracta Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.
8-K: Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer, Bolsters Leadership Team
Viracta Therapeutics has appointed Michael Faerm as its new Chief Financial Officer, effective May 13, 2024, bringing extensive experience in life sciences and finance to the company.
8-K: Viracta Therapeutics Announces Positive Clinical Trial Results and First Quarter 2024 Financials
Viracta Therapeutics reported positive topline results from its Phase 2 NAVAL-1 trial for Nana-val in relapsed or refractory EBV+ peripheral T-cell lymphoma and provided a business update along with first quarter 2024 financial results.
Viracta Therapeutics has regained compliance with Nasdaq's minimum bid price requirement after its stock price exceeded $1.00 for ten consecutive business days.
Viracta Therapeutics has announced the resignation of its Chief Financial Officer and Chief Operating Officer, Dan Chevallard, effective March 20, 2024, and appointed Melody Burcar as interim replacement.
Viracta Therapeutics has strengthened its financial position by securing a $5 million milestone payment and amending its loan agreement, extending its cash runway into mid-Q1 2025.